DailyIQ
Last updated9 minutes ago

ELAN·Elanco Animal Health Incorporated

$22.42
-0.14 (-0.62%)
Overnight$22.41-0.01 (-0.04%)
High
$22.77
Open
$22.63
Market Cap
11.30B
52W High
$28.20
Low
$22.22
P. Close
$22.42
P/E
-
52W Low
$19.17
Fwd P/E
17.44
DailyIQ Est.
$31.94
Inst. Ownership
43.4%
Short Interest
7.40%
Days to Cover
6.2
Technical Score (1D)
50
NEUTRAL
News Sentiment
52
MIXED
ELAN scores 50 on the 1D technical view with a NEUTRAL signal and mixed momentum. Price action is in a neutral range - the market is coiling, and neither side has been willing to push to a definitive break. Sentiment at 52 is diverging from the flat technical backdrop, removing sentiment as a directional catalyst for now. Consolidations like this are often a sign that the market is waiting for new information before committing capital in either direction. The range between $21.74 and $23.56 is well-defined. When this kind of compression resolves - particularly if it resolves with a gap or range-expansion bar - the follow-through tends to be more sustained than a typical breakout because of the energy that builds during the quiet phase. Coiled setups like this are as much about time as they are about price - the longer ELAN compresses between $21.74 and $23.56 without a catalyst, the more the eventual move tends to compensate. Watching for a volume spike on the actual break, rather than trying to anticipate direction from the shape of the range, has historically been the more reliable approach.
LOW TARGET
$26 +16.0%
1 analysts
MEAN TARGET
$31 +38.3%
12 analysts
HIGH TARGET
$34 +51.7%
12 analysts
PRICE RANGE
$26.00 - $34.00
SB / B / H / S / SS
10/11/2/1/1
DAILYIQ EST.
$31.94 (+42.5%)
Bought (1Y)
63,198 shares
$1.5M
Sold (1Y)
15,336 shares
$378K
VanHimbergen Robert MEVP and CFO
Award/Grant8.899 shares2026-10-02
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
Award/Grant127.684 shares2026-10-02
Modi Rajeev A.SEE REMARKS
Award/Grant66.709 shares2026-10-02
Anand Kapila K-
Award/Grant642.028 shares2026-09-30
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
Award/Grant126.09 shares2026-09-18
65/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✕Negative net margin
✓Positive operating cash flow
Gross Margin
55.0%
Net Margin
-4.9%
Revenue CAGR
5.5%
Current Ratio
2.17x
Debt / Equity
0.58x
Return on Equity
-3.5%

EPS

EstBeatMiss
$0.12$0.14$0.17$0.19$0.22Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.21 - -
Q3'25$0.13$0.19+43.9%

Revenue

EstBeatMiss
$1.1B$1.2B$1.2B$1.2B$1.2BQ3'25Q3'26
QtrEstActual+/−
Q3'26$1.2B - -
Q3'25 - $1.1B -

Market Data

ELAN Stock Snapshot

NEUTRAL50/100
$22.41−$0.01 (0.0%)
Market cap
11.30B
Day range
$22.22 – $22.77
News sentiment
52/100 · Neutral
Analyst target
$31.00 (+38.3%)
Consensus
Buy · 25 analysts
52-week range+16.9% off low · -20.5% from high
$19.17$28.20
Price $22.41 DailyIQ Est. $31.94

ELAN sits in the lower half of its 52-week range with the technical picture unresolved. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into ELAN?

RICH

At today's price, Elanco Animal Health Incorporated needs to grow free cash flow about 36.3% a year for the next 10 years to justify its valuation at a 9.97% cost of capital. Over its actual history it has compounded free cash flow at 18.4% a year, so the market is asking for 17.9 percentage points above its own delivered rate. On that basis ELAN looks priced above what its own growth record supports.

Implied FCF growth
36.3%
Historical FCF CAGR
18.4%
Growth gap
+17.9 pts
Verdict
RICH
Discount rate (WACC)
9.97%
Beta
1.18

Behaviour On Record

What ELAN's own history says about today's numbers

Realized volatility (21d)
19.5% 3rd pct
Below its peak
-37.6%
vs 200-day average
-3.8%
Up days (1y)
52%

Elanco Animal Health Incorporated is currently running 19.5% annualised volatility over the last 21 sessions. Measured against ELAN's own 8 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 39.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ELAN is trading -37.6% below its running peak. Across 7 full years on file, its median worst-drawdown-in-a-year was -36.9%, and the deepest was -60.6% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -3.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 46th percentile — close to the gap it normally carries. Over the past year ELAN closed higher on 52% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 8 years of records, ELAN finished the month higher 5 of 8 times, with a median return of +2.9% and an average of -1.6%. Its strongest month historically has been May at +8.8% on average, its weakest March at -8.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ELAN has opened more than 2% away from the prior close in 246 of 2,023 sessions (12.2% of the time), with the largest gaps running +10.9% and -12.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 2,024 daily closes between 2018-09-20 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against ELAN's own 8-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ELAN's sector?

Elanco Animal Health Incorporated sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, ELAN ranks 13th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#13 of 15

Options Market

What is the options market pricing for ELAN?

CallsPuts

For Elanco Animal Health Incorporated's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.32), with at-the-money implied volatility around 59.6%. The options market is pricing roughly a ±4.3% move by that expiry — a range of about $21.58–$23.54.

Put/call ratio (2026-10-16)
0.32
ATM implied volatility
59.6%
Total open interest
5,191
Expected move by 2026-10-16
±4.3% ($21.58–$23.54)

Analyst Rating Changes

Are analysts turning bullish or bearish on ELAN?

UBS most recently reiterated its rating on Elanco Animal Health Incorporated to Buy on Aug 6, 2026 with a price target of $33 (from $31). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 6, 2026UBSMaintainedBuy$31 → $33
Aug 6, 2026KeybancMaintainedOverweight$29 → $30
Jul 22, 2026Morgan StanleyMaintainedEqual-Weight$23 → $26
Jun 18, 2026TD CowenMaintainedBuy$31 → $32
May 7, 2026CitigroupMaintainedBuy$30 → $31
May 7, 2026JP MorganMaintainedOverweight$28 → $30
Apr 15, 2026CitigroupInitiatedBuy$30
Feb 25, 2026Morgan StanleyMaintainedEqual-Weight$22 → $24
Feb 25, 2026KeybancMaintainedOverweight$27 → $29
Feb 24, 2026Leerink PartnersMaintainedOutperform$26 → $30
Feb 19, 2026JP MorganMaintainedOverweight$24 → $28
Jan 22, 2026Piper SandlerUpgradeNeutral → Overweight$24 → $30

ETF holders

ETFs holding ELAN

News Sentiment Analysis

Sentiment gathered from recent headlines

52/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Elanco’s chief executive officer reflected on how growing up on a farm influenced his approach to business and animal welfare. He emphasized the importance of resilience, hands‑on problem solving, and a long‑term perspective in managing the company’s global operations. The piece highlighted his focus on sustainable practices and innovation in veterinary products. No direct financial guidance or earnings data were disclosed, and the article did not signal any immediate impact on the company’s valuation.
What did this article say?
Elanco Animal Health (NYSE:ELAN) conducted its second‑quarter 2026 earnings conference call on October 8. The company released a full transcript of the discussion, detailing its financial performance and strategic initiatives for the quarter. No specific earnings figures or forward guidance were disclosed in the provided excerpt. The transcript offers investors a comprehensive view of management’s commentary and Q&A session. Overall, the release provides routine information without indicating a material shift in the company’s outlook.
What did this article say?
Elanco Animal Health announced the opening of a 150,000‑square‑foot One Health Research Institute in Indianapolis, anchored by Purdue University. The facility will provide advanced laboratories, shared infrastructure, and collaboration spaces for animal health and veterinary partners. The partnership aims to accelerate discovery, diagnostics, translational science, and commercialization of One Health solutions. The project signals Elanco’s commitment to integrated research and could enhance its innovation pipeline. The announcement is viewed as a modest positive development for the company’s long‑term R&D strategy.
What did this article say?
Elanco (ELAN) reported muted 2% annual revenue growth over the past five years, while expenses rose, causing its adjusted operating margin to decline by 3.5 percentage points. The company’s negative returns on capital indicate that expansion efforts have not generated profitable growth. These financial pressures suggest that Elanco may struggle to maintain its competitive position in the animal health market.
What did this article say?
Elanco Animal Health CEO Jeff Simmons presented the company’s growth strategy at the Bank of America Healthcare Conference, highlighting a 10% reported growth split evenly between farm animal and pet health segments. The company emphasized a focus on growth, innovation, and cash generation, targeting mid‑single‑digit revenue growth, high‑single‑digit EBITDA growth, and low‑double‑digit earnings‑per‑share growth over the next three years. Elanco also committed to generating $1 billion in cash through 2028 while expanding margins annually and reducing debt.
What did this article say?
Elanco Animal Health (ELAN) presented at the Bank of America Global Healthcare Conference on September 22, 2026, outlining its 2026 strategic priorities and operational outlook. The company emphasized continued investment in its core pet health portfolio, expansion into emerging markets, and a focus on data‑driven product development. While the presentation reaffirmed existing guidance, no new financial targets or material catalysts were disclosed. The remarks suggest a steady, incremental growth trajectory rather than a significant upside or downside.
What did this article say?
Elanco Animal Health will participate in the BofA Securities Global Healthcare Conference on September 22, 2026, with CEO Jeff Simmons scheduled for a fireside chat. The event is a routine investor engagement with no new financial guidance or product announcements disclosed. The company’s presence signals ongoing commitment to investor relations but does not alter current valuation metrics.
What did this article say?
Elanco’s recent analysis highlights a sluggish 2% CAGR in sales over five years and a 3.5 percentage point drop in adjusted operating margin, signaling deteriorating profitability. The company’s stock has underperformed the S&P 500 and posted a modest 1.1% loss in the last six months, underscoring limited upside potential. Analysts recommend caution, suggesting investors consider alternative holdings given the weak growth trajectory and margin erosion.

Technical Analysis

Real-time indicators across multiple timeframes

50
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $5.26B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
FMR LLC (Fidelity)▲ Buy56,948,81911.30%$1.40B2026-08-13
BlackRock, Inc.▲ Buy48,849,9739.69%$1.20B2026-08-07
Vanguard Group Inc▼ Sell48,059,7319.53%$1.09B2026-01-29
Geode Capital Management, LLC▲ Buy11,302,0572.24%$278.20M2026-08-12
Citadel Advisors LLC▲ Buy9,668,6111.92%$237.94M2026-09-02
Morgan Stanley▲ Buy7,854,3621.56%$193.30M2026-08-13
Invesco Ltd.▼ Sell5,306,3261.05%$130.59M2026-08-14
Marshall Wace, LLP▲ Buy4,432,3500.88%$109.08M2026-08-13
Northern Trust Corp▲ Buy4,256,0560.84%$104.74M2026-08-13
Bank of America Corp▲ Buy3,909,8710.78%$96.22M2026-08-14
Capital World Investors▼ Sell2,813,6740.56%$69.24M2026-08-12
Millennium Management LLC▲ Buy2,725,8890.54%$67.08M2026-08-14
Wellington Management Group LLP▼ Sell2,676,0500.53%$65.86M2026-08-14
JPMorgan Chase & Co▼ Sell1,922,8990.38%$48.12M2026-08-12
Adage Capital Partners GP, L.L.C.▲ Buy1,456,5690.29%$35.85M2026-08-14
Goldman Sachs Group Inc▼ Sell1,412,1900.28%$34.75M2026-08-14
Wells Fargo & Company▲ Buy976,3610.19%$24.03M2026-08-14
AllianceBernstein L.P.▼ Sell621,6750.12%$14.88M2026-08-14
Gotham Asset Management, LLC▲ Buy465,7140.09%$11.46M2026-08-14
ExodusPoint Capital Management, LP▼ Sell446,1790.09%$10.98M2026-08-14
Prudential Financial Inc▼ Sell424,1670.08%$10.44M2026-08-12
Norges Bank▼ Sell391,3170.08%$9.63M2026-08-12
Citigroup Inc▲ Buy257,2550.05%$6.33M2026-08-03
Verition Fund Management LLC▲ Buy250,0000.05%$6.15M2026-08-14
AQR Capital Management LLC▲ Buy224,3110.04%$5.45M2026-08-14
Q2 2026 flow:20.18M sh bought ($496.61M)5.04M sh sold ($123.95M)net +15.14M sh (+$372.66M)
Congressional Trading Activity
2 disclosed trades · ~$16.0K est. traded value · 0 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Dan SullivanSenateAK▼ Sell$1K - $15K2022-11-302023-07-26